ストックスクリーナーアプリを入手
51.91
1.01%
-0.53
前日終値:
$52.44
開ける：
$53.07
24時間の取引高:
6.54M
Relative Volume:
2.54
時価総額：
$13.05B
収益：
$2.38B
当期純損益:
$833.42M
株価収益率:
17.20
EPS:
3.0172
ネットキャッシュフロー:
$917.69M
1週間 パフォーマンス:
-2.97%
1か月 パフォーマンス:
+4.15%
6か月 パフォーマンス:
+21.94%
1年 パフォーマンス:
+27.42%
1日の値動き範囲:
$50.96
$53.12
1週間の範囲:
$50.96
$53.87
52週間の値動き範囲:
$33.76
$53.93
Exelixis Inc Stock (EXEL) Company Profile
Compare EXEL vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
51.91 | 13.05B | 2.38B | 833.42M | 917.69M | 3.0172 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-11-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 開始されました | Goldman | Buy |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
Exelixis Stockweekly review and biotech sector context - AD HOC NEWS
Here's why Exelixis (EXEL) is a strong momentum stock - MSN
Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Exelixis Inc (EXEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Exelixis Inc (EXEL) Institutional Confidence - TradingKey
Exelixis Inc (EXEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Exelixis Inc (EXEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Exelixis Inc (EXEL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results - AD HOC NEWS
Why (EXEL) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions - Yahoo Finance
Exelixis, Inc. (EXEL) stock price, news, quote and history - Yahoo Finance UK
Exelixis, Inc. (EXEL) Latest Stock News & Headlines - Yahoo Finance
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight - GlobeNewswire Inc.
Exelixis Hits High on Growing Sales, Institutional Inflows - Yahoo Finance
Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL - MarketBeat
Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis stock hits all-time high at 52.98 USD By Investing.com - Investing.com Canada
Exelixis stock hits all-time high at 52.98 USD - Investing.com
Exelixis Inc (NASDAQ:EXEL) Offers Decent Value with Strong Profitability and Financial Health - ChartMill
Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL - MarketBeat
· Analyst Forecast - MLQ.ai
Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co. - MarketBeat
Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth - DirectorsTalk Interviews
Los Angeles Capital Management LLC Has $49.57 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Commonwealth Equity Services LLC Sells 259,643 Shares of Exelixis, Inc. $EXEL - MarketBeat
168,437 Shares in Exelixis, Inc. $EXEL Purchased by WINTON GROUP Ltd - MarketBeat
Norges Bank Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
EULAV Asset Management Trims Stock Position in Exelixis, Inc. $EXEL - MarketBeat
CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations - Sahm
Exelixis (NASDAQ:EXEL) Reaches New 52-Week HighTime to Buy? - MarketBeat
Why Exelixis (EXEL) is a top growth stock for the long term - MSN
Exelixis, Inc. (EXEL) latest stock news and headlines - Yahoo Finance UK
Exelixis, Inc. (EXEL) Stock Price, News, Quote & History - Yahoo Finance
Exelixis (EXEL) Up 6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Marietta Investment Partners LLC Has $815,000 Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Understanding Momentum Shifts in (EXEL) - Stock Traders Daily
Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis Inc at Jefferies Global Healthcare Conference in New York Transcript - GuruFocus
Exelixis director Jack Wyszomierski sells $198,408 in shares By Investing.com - Investing.com Australia
Exelixis director Jack Wyszomierski sells $198,408 in shares - Investing.com UK
Exelixis director Sue Eckhardt sells $491,973 in stock - Investing.com UK
Exelixis director Sue Eckhardt sells $491,973 in stock By Investing.com - Investing.com Australia
Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski - Stock Titan
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):